GlassScriptPhysician profile
Jeremiah Powers
NPI 1104451830
$5,624.90
in general payments reported to CMS, 2019-2025
41 companies · $799 in 2025
The $799 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,753 · 2022: $881 · 2023: $1,052 · 2024: $1,140 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,991.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,378.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $937.75 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $501.21 | 2021-2025 | |
| Esperion Therapeutics, INC. | $394.48 | 2021-2022 | |
| Pfizer INC. | $384.41 | 2021-2025 | |
| Amgen INC. | $313.80 | 2021-2024 | Enbrel, Evenity, Prolia |
| Lilly USA, LLC | $281.23 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $246.75 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $127.09 | 2023-2024 | Rexulti |
| Shield Therapeutics INC | $119.77 | 2024 | |
| Glaxosmithkline, LLC. | $114.15 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Corcept Therapeutics | $92.20 | 2024-2025 | Korlym |
| Sanofi Pasteur INC. | $59.33 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $50.37 | 2021 | |
| Merck Sharp & Dohme LLC | $45.45 | 2022-2024 | Gardasil 9, Vaxelis, Vaqta |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.